Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TESTOSTERONE CYPIONATE-ESTRADIOL CYPIONATE vs ANDROID 10
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Testosterone cypionate is a prodrug of testosterone, which binds to androgen receptors and modulates gene expression, promoting male secondary sex characteristics and anabolic effects. Estradiol cypionate is a prodrug of estradiol, which binds to estrogen receptors and regulates gene transcription involved in female reproductive development and maintenance.
Androgen receptor agonist; testicular androgen responsible for development and maintenance of male sex characteristics and anabolic effects; increases protein synthesis and muscle mass.
Moderate to severe vasomotor symptoms due to menopause (estradiol component, off-label for testosterone),Male hypogonadism (testosterone component)
Male hypogonadism (primary and hypogonadotropic),Delayed puberty in males,Off-label: Androgen replacement in transgender men (masculinizing hormone therapy)
Testosterone cypionate 50-200 mg and estradiol cypionate 2-10 mg intramuscularly every 2-4 weeks.
Testosterone undecanoate 750 mg (3 m L) intramuscular injection every 10 weeks, or testosterone cypionate 50-400 mg intramuscular injection every 2-4 weeks. For gel formulations: 50-100 mg transdermally once daily.
Testosterone cypionate: approximately 8 days; estradiol cypionate: approximately 8-10 days. Clinical context: steady-state reached in 3-5 weeks.
8 hours; clinical context: steady-state achieved in 2-3 days, dosing interval 8-12 hours.
Testosterone cypionate: Hydrolyzed to testosterone then metabolized primarily in the liver via oxidation (CYP3A4, CYP2C9) and conjugation; estradiol cypionate: Hydrolyzed to estradiol then metabolized via hydroxylation (CYP1A2, CYP3A4) and glucuronidation.
Hepatic metabolism via CYP3A4; undergoes extensive first-pass metabolism; metabolites primarily excreted renally.
Renal (90% as glucuronide and sulfate conjugates, less than 5% as unchanged drug); fecal (approximately 10%).
Renal: 90% as glucuronide and sulfate conjugates, 6% as unchanged drug; fecal: 4%.
Testosterone: 97-99% bound to sex hormone-binding globulin (SHBG) and albumin; estradiol: 98% bound to SHBG and albumin.
97-99% bound primarily to sex hormone-binding globulin (SHBG) and albumin.
Testosterone: approximately 0.6 L/kg; estradiol: approximately 0.5 L/kg. Indicates distribution into peripheral tissues.
0.5-1.0 L/kg; indicates extensive distribution into tissues and organs.
Intramuscular: approximately 100% due to slow release from oil depot; no oral bioavailability (hepatic first-pass inactivation).
Oral: low (variable, ~5-20% due to first-pass metabolism); intramuscular: 100%.
No specific dose adjustment recommended; use with caution in severe impairment due to limited data.
No specific dose adjustment required for renal impairment; monitor serum testosterone levels and clinical response. For severe renal impairment (GFR <30 m L/min), consider increased monitoring due to potential fluid retention.
Contraindicated in severe hepatic impairment (Child-Pugh C). For mild to moderate (Child-Pugh A or B), use with caution and monitor hepatic function.
Contraindicated in patients with severe hepatic dysfunction (Child-Pugh class C). For mild to moderate impairment (Child-Pugh class A or B), use with caution and consider dose reduction; monitor liver function tests regularly.
Not recommended for pediatric use; safety and efficacy not established.
Not recommended for use in children; safety and efficacy not established. For delayed puberty in adolescent males: testosterone enanthate 50-200 mg intramuscularly every 2-4 weeks, titrated to response, with monitoring of bone age.
Use lower end of dosing range (e.g., testosterone cypionate 50-100 mg with estradiol cypionate 2-5 mg every 4 weeks) due to increased risk of cardiovascular and prostate adverse effects; monitor closely.
Start at low end of dosing range (e.g., testosterone cypionate 50 mg intramuscularly every 4 weeks or gel 25 mg daily) due to potential increased sensitivity and risk of prostatic hypertrophy or cardiovascular events. Monitor serum testosterone, hematocrit, and prostate-specific antigen (PSA).
Estrogens, with or without progestins, should not be used for the prevention of cardiovascular disease or dementia. Increased risks of endometrial cancer, stroke, and deep vein thrombosis. Venous thromboembolism risk is increased with estrogen-containing products.
None
Cardiovascular risk: increased risk of myocardial infarction, stroke, venous thromboembolism,Endometrial cancer: unopposed estrogen use increases risk,Breast cancer: caution in patients with known or suspected estrogen-dependent tumors,Hepatic impairment: dose adjustment may be needed,Hypercalcemia: caution in patients with bone metastases,Fluid retention: caution in cardiac or renal dysfunction
Risk of hepatotoxicity; use with caution in patients with liver disease. Monitor liver function, lipid profile, and prostate-specific antigen (PSA). May cause fluid retention, gynecomastia, priapism, and sleep apnea. Not for use in women who are pregnant or breastfeeding. May accelerate growth of prostate cancer and benign prostatic hyperplasia. Androgenic effects may cause virilization in women.
Pregnancy (estrogen component),Breast cancer (known, suspected, or history, unless appropriate indication),Estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Active thromboembolic disease or history of thromboembolism (e.g., DVT, PE),Known hypersensitivity to components,Men with prostate or breast cancer (testosterone component)
Men with carcinoma of the prostate or breast; history of hypersensitivity to testosterone or any component; women who are pregnant or may become pregnant (risk of fetal harm); patients with severe hepatic or cardiac disease.
Avoid excessive grapefruit juice as it may affect hormone metabolism. No specific food interactions; maintain a balanced diet.
No known food interactions. However, methyltestosterone can increase appetite and cause weight gain; a balanced diet is recommended.
First trimester: High risk of masculinization of female fetus. Second trimester: Androgenic effects may cause clitoral enlargement, labial fusion, and urogenital sinus abnormalities. Third trimester: Possible advanced bone age and growth acceleration. Not recommended in any trimester.
Android 10 is a combination of methyltestosterone and ethinyl estradiol. Methyltestosterone is an androgen; exposure during pregnancy, particularly during the first trimester, can cause virilization of the female fetus. Ethinyl estradiol is contraindicated in pregnancy due to risk of fetal harm. Use is contraindicated in all trimesters.
Contraindicated during breast-feeding. Excreted in breast milk, may cause masculinization of female infant. M/P ratio not known.
Methyltestosterone and ethinyl estradiol are excreted in breast milk. Methyltestosterone may cause virilization in female infants. Ethinyl estradiol may reduce milk production and quality. M/P ratio not available. Breastfeeding is contraindicated.
Not recommended for use during pregnancy; dose adjustment is not applicable.
Contraindicated in pregnancy; no dosing adjustments apply. If inadvertent use occurs, discontinue immediately.
Monitor for signs of thromboembolism, especially in patients with risk factors. Measure serum testosterone and estradiol levels periodically to maintain therapeutic range. Use with caution in patients with history of myocardial infarction or stroke. Contraindicated in men with breast or prostate cancer. May cause gynecomastia and fluid retention.
Android 10 is a brand name for methyltestosterone, an androgen and anabolic steroid. Use is restricted to replacement therapy in males with hypogonadism or delayed puberty due to androgen deficiency. Monitor liver function due to risk of peliosis hepatis and hepatocellular carcinoma. Contraindicated in males with breast or prostate cancer. Can cause erythrocytosis; monitor hematocrit. Discontinue if signs of virilization in women or priapism in men. Use caution in elderly due to increased risk of prostatic hypertrophy.
Report any signs of blood clots (leg pain, chest pain, shortness of breath) immediately.,Do not use if you are pregnant or breastfeeding.,Regular blood tests are required to monitor hormone levels and liver function.,Use as prescribed; do not adjust dose without consulting your healthcare provider.,Inform your doctor about all medications you are taking, including over-the-counter drugs.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Report signs of liver problems: yellowing of skin or eyes, dark urine, light-colored stools, abdominal pain.,Notify your doctor if you experience swelling of ankles or feet, trouble breathing, or persistent erections lasting more than 4 hours.,May cause aggressive behavior, mood swings, or depression; contact your doctor if these occur.,Do not take if you are pregnant or breastfeeding.,Keep all appointments for blood tests and liver function monitoring.
"Estradiol (estrogen) may reduce the anticoagulant effect of warfarin, likely by enhancing the synthesis of clotting factors (e.g., factors II, VII, IX, X) in the liver. This interaction can lead to a decrease in the International Normalized Ratio (INR) and potentially increase the risk of thromboembolic events. Conversely, when estradiol is discontinued, warfarin's effect may increase, raising the risk of bleeding."
"Acitretin, a retinoid used for psoriasis, induces CYP3A4 enzymes, accelerating estradiol metabolism and reducing its systemic exposure. This can lead to decreased contraceptive efficacy of estrogen-containing oral contraceptives, potentially resulting in unplanned pregnancy. Additionally, acitretin itself is teratogenic, making effective contraception critical during therapy."
"The combination of Halcinonide, a potent topical corticosteroid, with Estradiol may lead to increased systemic absorption of Estradiol due to corticosteroid-induced inhibition of estrogen metabolism via competition for cytochrome P450 enzymes, particularly CYP3A4. This interaction can result in elevated estradiol serum concentrations, potentially augmenting estrogenic effects such as thromboembolic risk, endometrial hyperplasia, and hormonal imbalance. Clinically, patients may experience symptoms like breakthrough bleeding, breast tenderness, or worsened side effects of estrogen therapy."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TESTOSTERONE CYPIONATE-ESTRADIOL CYPIONATE vs ANDROID 10, answered by our medical review team.
TESTOSTERONE CYPIONATE-ESTRADIOL CYPIONATE is a Androgen that works by Testosterone cypionate is a prodrug of testosterone, which binds to androgen receptors and modulates gene expression, promoting male secondary sex characteristics and anabolic effects. Estradiol cypionate is a prodrug of estradiol, which binds to estrogen receptors and regulates gene transcription involved in female reproductive development and maintenance.. ANDROID 10 is a Androgen that works by Androgen receptor agonist; testicular androgen responsible for development and maintenance of male sex characteristics and anabolic effects; increases protein synthesis and muscle mass.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TESTOSTERONE CYPIONATE-ESTRADIOL CYPIONATE and ANDROID 10 depend on the specific clinical indication. These are both Androgen agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TESTOSTERONE CYPIONATE-ESTRADIOL CYPIONATE is: Testosterone cypionate 50-200 mg and estradiol cypionate 2-10 mg intramuscularly every 2-4 weeks.. The standard adult dose of ANDROID 10 is: Testosterone undecanoate 750 mg (3 m L) intramuscular injection every 10 weeks, or testosterone cypionate 50-400 mg intramuscular injection every 2-4 weeks. For gel formulations: 50-100 mg transdermally once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TESTOSTERONE CYPIONATE-ESTRADIOL CYPIONATE and ANDROID 10 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TESTOSTERONE CYPIONATE-ESTRADIOL CYPIONATE is classified as Category D/X. First trimester: High risk of masculinization of female fetus. Second trimester: Androgenic effects may cause clitoral enlargement, labial fusion, and urogenital sinus abnormalitie. ANDROID 10 is classified as Category C. Android 10 is a combination of methyltestosterone and ethinyl estradiol. Methyltestosterone is an androgen; exposure during pregnancy, particularly during the first trimester, can . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.